7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Arterial thrombosis; Catheter thrombosis; Venous thrombosis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms EINSTEIN; Einstein Jr
- Sponsors Bayer; Bayer HealthCare
- 24 Dec 2017 This trial has been completed in Finland (end date: 18 Dec 2017).
- 20 Oct 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2018.
- 04 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.